MoonLake Immunotherapeutics MLTX
12.04
(0.08)
(0.66%)
as of 25 Sep
- Market cap
- $1.0B
- P/E
- 0.0×
Follow MLTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.51%) | (59.99%) | (77.13%) | (67.08%) | |
| (45.14%) | (50.38%) | (56.40%) | (51.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.91%) | (60.33%) | (73.23%) | (50.21%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.93) | (3.04) | (3.14) | (3.05) | |
Free Cash Flow |
(185.90) | (196.04) | (224.15) | (225.18) | |
Capital Expenditures |
(0.21) | (0.03) | — | — | |
| Other line items | |||||
Cash ROIC |
(24.91%) | (25.37%) | (31.53%) | (21.15%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.86 | 0.87 | 0.85 | |
Depreciation/Fixed assets |
3.58 | 4.53 | 5.80 | 6.65 | |
Capex/Depreciation |
(0.09) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.93) | (3.04) | (3.14) | (3.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates